Additional Study Information: The purpose of this registry study is to assess information obtained from the Agendia Breast Cancer Suite of diagnostic tests and other clinical information to study ways to assist in breast cancer diagnosis and treatment decisions in Chinese patients. The Agendia Breast Cancer Suite includes MammaPrint, TargetPrint, BluePrint, and TheraPrint which are tests that help your doctor analyze and profile your breast cancer tumor. This study is for patients who are being treated for breast cancer and have received the MammaPrint, BluePrint and TargetPrint assays. As part of your routine breast cancer treatment, your doctor will provide tissue from your tumor to Agendia for testing. The Agendia Breast Cancer Suite of diagnostic tests will be performed on tumor tissue shipped to Agendias CAP and CLIA-certified laboratory in Irvine, CA. Your doctor will receive the results of theBreast Cancer Suite to assist in your treatment. If you decide to participate in this study, Agendia will store the results of your diagnostic tests in a database with other clinical data about you and your cancer collected from your doctor. Your doctor will be asked to provide data to Agendia after results of MammaPrint, BluePrint and TargetPrint are known.